Recent Updates
Recently added Catalysts
PRAX Positive Sentiment

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Tuesday, April 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Praxis Precision Medicines is set to host a virtual investor event on May 2, 2025, to discuss its clinical programs for developmental and epileptic encephalopathies. The management will provide insights into ongoing studies, including evaluations of relutrigine and elsunersen for various DEEs. Registration details for the event have been provided, and a replay will be available afterward.
Price reaction · baseline $31.53 (2025-04-07 close) · hit after-hours · clean, no other PRAX news in the window
day 0 close · peak
-9.3%
day 1
-2.2%
day 3
-5.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Praxis is actively engaging with investors through a virtual event.
  • The company is focusing on clinical programs targeting serious CNS disorders.
  • Studies on the effectiveness of relutrigine and elsunersen show potential promise.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+61%
120-day peak, hindsight
Typical move
23.7%
average across 12 past catalysts
Cash runway
~53 mo
Minimal dilution risk
Lead asset
vormatrogine
Phase 3 · Epilepsy, Tonic-Clonic

Full Press Release Details

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT.
The webinar, hosted by the Praxis management team, will focus on the company’s clinical programs in developmental and epileptic encephalopathies (DEEs) including:
The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs
The EMERALD study evaluating relutrigine for broader DEEs
The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE
To RSVP and attend the live event, you may click here.   A replay of the webinar will also be available through the “Events & Presentations” page under the “Investors + Media” section of the company’s website for 90 days.

Frequently Asked Questions

What is the purpose of the virtual investor event on May 2, 2025?

The event aims to discuss Praxis's clinical programs for developmental and epileptic encephalopathies.

What studies will be featured during the investor webinar?

Featured studies include EMBOLD, EMERALD, and EMBRAVE3, all focusing on DEEs.

How can I attend the Praxis investor event?

You can RSVP for the live event through a link provided in the announcement.

Will there be a replay of the webinar available?

Yes, a replay will be accessible on the company's website for 90 days.

Who is hosting the virtual investor event?

The event will be hosted by the management team of Praxis Precision Medicines.

ShareAdd on Google
Tags: PRAX Viatris Investor Conferences Healthcare CNS disorders DEEs relutrigine elsunersen
Last updated: Apr 8, 2025

Biotech snapshot

Cash runway
$1374M liquidity · $26M/mo burn
~53 mo
Minimal dilution risk
Lead asset
vormatroginePhase 3
Epilepsy, Tonic-Clonic →

Catalyst track record

+61%
best trade around PRAX's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for PRAX.

See every catalyst's timing & PoA →